Autism spectrum disorder: prospects for treatment using gene therapy.

作者: Matthew Benger , Maria Kinali , Nicholas D. Mazarakis

DOI: 10.1186/S13229-018-0222-8

关键词:

摘要: Autism spectrum disorder (ASD) is characterised by the concomitant occurrence of impaired social interaction; restricted, perseverative and stereotypical behaviour; abnormal communication skills. Recent epidemiological studies have reported a dramatic increase in prevalence ASD with as many 1 every 59 children being diagnosed ASD. The fact that appears to be principally genetically driven, may reversible postnatally, has raised exciting possibility using gene therapy disease-modifying treatment. Such therapies already started seriously impact on human disease particularly monogenic disorders (e.g. metachromatic leukodystrophy, SMA type 1). In regard ASD, technical advances both our capacity model animals also ability deliver genes central nervous system (CNS) led first preclinical involving replacement silencing. Furthermore, increasing awareness understanding common dysregulated pathways broadened therapy’s potential scope include various polygenic ASDs. As this review highlights, despite number outstanding challenges, excellent address cognitive dysfunction

参考文章(136)
Shilpa Prabhakar, Xuan Zhang, June Goto, Sangyeul Han, Charles Lai, Roderick Bronson, Miguel Sena-Esteves, Vijaya Ramesh, Anat Stemmer-Rachamimov, David J. Kwiatkowski, Xandra O. Breakefield, Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. Neurobiology of Disease. ,vol. 82, pp. 22- 31 ,(2015) , 10.1016/J.NBD.2015.04.018
Ruthie E. Amir, Ignatia B. Van den Veyver, Mimi Wan, Charles Q. Tran, Uta Francke, Huda Y. Zoghbi, Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nature Genetics. ,vol. 23, pp. 185- 188 ,(1999) , 10.1038/13810
Translational animal models of autism and neurodevelopmental disorders. Dialogues in clinical neuroscience. ,vol. 14, pp. 293- 305 ,(2012) , 10.31887/DCNS.2012.14.3/JCRAWLEY
Nancy Smyth Templeton, None, Gene and cell therapy : therapeutic mechanisms and strategies Marcel Dekker. ,(2004)
Luigi Naldini, Gene therapy returns to centre stage Nature. ,vol. 526, pp. 351- 360 ,(2015) , 10.1038/NATURE15818
Anila M. D'Mello, Catherine J. Stoodley, Cerebro-cerebellar circuits in autism spectrum disorder Frontiers in Neuroscience. ,vol. 9, pp. 408- 408 ,(2015) , 10.3389/FNINS.2015.00408
Yuk Jing Loke, Anthony John Hannan, Jeffrey Mark Craig, The role of epigenetic change in autism spectrum disorders Frontiers in Neurology. ,vol. 6, pp. 107- 107 ,(2015) , 10.3389/FNEUR.2015.00107
Jerry Skefos, Christopher Cummings, Katelyn Enzer, Jarrod Holiday, Katrina Weed, Ezra Levy, Tarik Yuce, Thomas Kemper, Margaret Bauman, Regional Alterations in Purkinje Cell Density in Patients with Autism PLoS ONE. ,vol. 9, pp. e81255- ,(2014) , 10.1371/JOURNAL.PONE.0081255
Hilde Van Esch, Marijke Bauters, Jaakko Ignatius, Mieke Jansen, Martine Raynaud, Karen Hollanders, Dorien Lugtenberg, Thierry Bienvenu, Lars Riff Jensen, Jozef Gécz, Claude Moraine, Peter Marynen, Jean-Pierre Fryns, Guy Froyen, Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. American Journal of Human Genetics. ,vol. 77, pp. 442- 453 ,(2005) , 10.1086/444549
B. M. Dolan, S. G. Duron, D. A. Campbell, B. Vollrath, B. S. S. Rao, H.-Y. Ko, G. G. Lin, A. Govindarajan, S.-Y. Choi, S. Tonegawa, Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 110, pp. 5671- 5676 ,(2013) , 10.1073/PNAS.1219383110